-
Post-ASCO GI 2025 | Professors Kefeng Ding and Ying Yuan Discuss the BBCAPX Study: A New Path Forward in Immunotherapy for RAS-Mutant/MSS Unresectable
Following the presentation, Professor Kefeng Ding joined Professor Yuan in a dialogue reflecting on the key progress of the study and its future direction, rekindling hope for immunotherapy in this…
-
Prof. Chunfang Hao: Highlights from the Updated CSCO Guidelines for HR+ mBC – A Dual Emphasis on Endocrine Combination Therapy and Precision Testing
The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, featured the highly anticipated update to the CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer (CSCO BC Guidelines). The latest edition further refines stratified treatment strategies and emphasizes the importance of both precision medicine and combination therapies—providing more detailed…
-
In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout
As the 2025 Annual Meeting of the National Comprehensive Cancer Network (NCCN) concluded, Oncology Frontier exclusively interviewed Dr. Wui-Jin Koh, Chief Medical Officer of NCCN, to decode the future trends in cancer care. From the application prospects of AI-assisted medical decision-making to the inclusive practice of decentralized clinical trials, from the systemic challenges of combating…
-
ELCC 2025 | Professor Wenxiu Yao Shares Insights on the Latest Advances in ADC Therapy for Lung Cancer
At the 2024 European Lung Cancer Congress (ELCC) held in Paris, Oncology Frontier conducted an exclusive interview with Professor Wenxiu Yao from Sichuan Cancer Hospital. Professor Yao provided in-depth commentary on the latest research presented at the congress regarding antibody-drug conjugates (ADCs) in the treatment of lung cancer.
-
ELCC 2025 | Professor Rui Ma on the Final OS Results from the MARIPOSA Study
The 2025 European Lung Cancer Congress (ELCC) officially opened on March 26 in Paris, France. On the very first day, during the Proffered Paper Session 1, the highly anticipated final overall survival (OS) results from the MARIPOSA study (Abstract 4O) were presented.Oncology Frontier invited Professor Rui Ma of Liaoning Cancer Hospital to provide an in-depth…
-
ELCC 2025 | Professor Gen Lin: Promising Results for Osimertinib Plus Dato-DXd in TKI-Resistant NSCLC from the ORCHARD Study
At the 2025 European Lung Cancer Congress (ELCC), new data from the ORCHARD study were presented, highlighting the potential of osimertinib in combination with Dato-DXd as a post-progression strategy following first-line osimertinib treatment in patients with EGFR-mutant non-small cell lung cancer (NSCLC). This marks the first public release of efficacy and safety findings for this…
-
ELCC 2025 | Professor Lin Wu: Long-Term Benefit and Individualized Dose Reduction Strategies of Domestic Third-Generation EGFR-TKI in EGFR T790M-Mutated NSCLC
At the 2025 European Lung Cancer Congress (ELCC), the team led by Professor Lin Wu from the Hunan Cancer Hospital, Xiangya Hospital, Central South University, presented long-term follow-up data on ASK120067 (rezivertinib) in patients with locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer (NSCLC). Oncology Frontier invited Professor Wu to comment on the…
-
ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition
The recently concluded 2025 European Lung Cancer Congress (ELCC) spotlighted several key clinical topics and unveiled new research with strong translational potential. Oncology Frontier invited Professor Wei Zhang of Shanghai Chest Hospital, Shanghai Jiao Tong University for an in-depth interview, where she shared expert insights on the congress’s most impactful themes and dissected the scientific…
Connecting Medical Expertise through Media